Outpatient Surgery Magazine, providing current information on Surgical Services, Surgical Facility Administration, Outpatient Surgery News and Trends, OR Excellence and more.
Issue link: http://outpatientsurgery.uberflip.com/i/836658
d. The tray is disorganized with lots of clutter e. all of the above e. Personal items on a tray pose an infection control risk, while a disor- ganized workplace means you're more likely to grab the wrong thing. 9. Where can you access and use sterile injectable multi-dose medications for mul- tiple patients? a. in the operating room b. at the patient bed- side c. in the medication room d. on the medication cart in the OR hallway c. Whenever possible, dedicate multi-dose vials to a single patient. Should you use multi-dose vials for more than one patient, store and access the vial in a dedicated medication preparation area (med- ication room or nurses J U N E 2 0 1 7 • O U T PA T I E N TS U R G E R Y. N E T • 3 1 Important Safety Information The use of The use of Revonto in the management of malignant hyperthermia crisis is not a substitute for previously known supportive measures. These measures must be individualized, but it will usually be necessary to discontinue the suspect triggering agents, attend to increased oxygen requirements, manage the metabolic acidosis, institute cooling when necessary, monitor urinary output, and monitor for electrolyte imbalance. Patients who receive i.v. dantrolene sodium preoperatively should have vital signs monitored. If patients judged malignant hype If patients judged malignant hyperthermia susceptible are administered dantrolene sodium preoperatively, anesthetic preparation must still follow a standard malignant hyperthermia susceptible regimen, including the avoidance of known triggering agents. Monitoring for early clinical and metabolic signs of malignant hyperthermia is indicated because attenuation of malignant hyperthermia, rather than prevention, is possible. Despite initial satisfacto Despite initial satisfactory response to i.v. dantrolene there have been reports of fatality, which involve patients who could not be weaned from dantrolene after initial treatment. The administration of i.v. dantrolene is associated with loss of grip strength and weakness in the legs, as well as drowsiness and dizziness. There have been reports of thrombophlebitis following administration of intravenous dantrolene. Tissue necrosis secondary to extravasation has been reported. Injection site reactions (pain, erythema, swelling), commonly due to extravasation, have been reported. Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therap liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy. To report SUSPECTED ADVERSE REACTIONS contact US WorldMeds at 1-888-900-8796 or MEDWATCH at 1-800-FDA-1088 (1-800-332-1088) or http://www.FDA.gov/medwatch/. To see the full prescribing information visit www.revonto.com. © 2017. US WorldMeds, LLC. Revonto is a registered trademark of US WorldMeds, LLC. REV-P91-0217 ® 36 month shelf life* Ready to administer in 20 seconds † Are You Prepared for a CRISIS? Visit www.revonto.com or call (877) 411-USWM (8796) to learn more and to see the full Prescribing Information. *from the date of manufacture † or until solution is clear